Axsome Therapeutics's Q2 revenue rises 72% to $150 mln
Overview
Axsome Q2 2025 net product revenue grows 72% yr/yr to $150 mln
AUVELITY sales increase 84% yr/yr, driving revenue growth
Net loss narrows to $48 mln from $79.3 mln in prior year
Outlook
Axsome plans AXS-05 sNDA submission for Alzheimer's agitation in 3Q 2025
Company expects AXS-12 NDA submission for narcolepsy in 4Q 2025
Axsome to initiate Phase 3 trials for solriamfetol in ADHD, MDD in 4Q 2025
Company confident current cash will fund operations to cash flow positivity
Result Drivers
AUVELITY SALES - AUVELITY sales grew 84% yr/yr to $119.6 mln, driven by expanded market access with 28 mln new covered lives
SUNOSI GROWTH - SUNOSI sales increased 35% yr/yr to $30 mln, supported by strong prescription growth
SYMBRAVO LAUNCH - SYMBRAVO launched in June, contributing $0.4 mln to Q2 revenue
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | -$0.97 | ||
Q2 Net Income | -$47.97 mln | ||
Q2 Operating Expenses | $186.76 mln | ||
Q2 Operating Income | -$36.71 mln | ||
Q2 Pretax Profit | -$48.93 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Axsome Therapeutics Inc is $181.50, about 43.2% above its August 1 closing price of $103.02
Press Release:
